Stockreport

Sana Biotechnology Announces Positive Six-Month Clinical Results from Type 1 Diabetes Study of Islet Cell Transplantation Without Immunosuppression [Yahoo! Finance]

Sana Biotechnology, Inc.  (SANA) 
PDF Six-Month Patient Follow-up Results Demonstrate that Sana's Transplanted Pancreatic Islet Cells Modified with its Hypoimmune (HIP) Technology are Safe and Well-tolerate [Read more]